CCHT's subsidiary has received approval for the clinical trial application for the domestic production of the injectable GenSci143 drug
CCHT's subsidiary Changchun Jinsai Pharmaceutical recently received approval from the National Medical Products Administration to conduct clinical trials for the injectable GenSci143. This drug is a Class 1 biological product primarily used for the treatment of advanced solid tumors such as prostate cancer and lung cancer, with dual potential for targeted chemotherapy and tumor immunotherapy, aimed at overcoming tumor heterogeneity and resistance
According to the Zhitong Finance APP, Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun JinSai Pharmaceutical Co., Ltd. (hereinafter referred to as "JinSai Pharmaceutical"), has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration, approving the clinical trial of GenSci143 injection in patients with advanced solid tumors.
GenSci143 is a Class 1 therapeutic biological product independently developed by JinSai Pharmaceutical, intended for the treatment of various advanced solid tumors such as prostate cancer and lung cancer. As a bispecific antibody-drug conjugate (BsADC) targeting B7-H3 and PSMA, GenSci143 has dual potential therapeutic effects of targeted chemotherapy and tumor immunotherapy, capable of overcoming tumor heterogeneity and resistance caused by reduced expression of a single target, thereby covering more patients and producing more durable anti-tumor efficacy
